Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer

British Journal of Cancer

Volumn 81, Issue 3, 1999, Pages 537-541

  Hsieh, F I ^a   Pu, Y S ^b   Chern, H D ^c   Hsu, L I ^a   Chiou, H Y ^b   Chen, C J ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Bladder cancer; Cigarette smoking; N acetyltransferase 1; N acetyltransferase 2

Indexed keywords

ACYLTRANSFERASE; AROMATIC AMINE;

ACETYLATOR PHENOTYPE; ARTICLE; BLADDER CANCER; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; METABOLISM; OCCUPATIONAL EXPOSURE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; QUESTIONNAIRE; UNIVERSITY HOSPITAL;

ACETYLATION; AGED; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; CARCINOMA, TRANSITIONAL CELL; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; ODDS RATIO; PLANTS, TOXIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; SMOKING; TAIWAN; TIME FACTORS; TOBACCO; URINARY BLADDER NEOPLASMS;

EID: 0032837276     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690727     Document Type: Article

References (32)

1. Augustine A, Hebert JR, Kabat GC and Wynder EL (1988) Bladder cancer in relation to cigarette smoking. Cancer Res 48: 4405-4408
2. Bartsch H, Malaveille C, Friesen M, Kadlubar FF and Vineis P (1993) Black (ari-cured) and blond (flue-cured) tobacco cancer risk IV: molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur J Cancer 29A: 1199-1207.
3. Bell DA, Taylor JA, Butler MA, Stephens E, Wiest J, Brubaker L, Kadlubar FF and Lucier GW (1993) Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14: 1689-1692
4. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF and Hirvonen A (1995a) Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 55: 5226-5229.
5. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J and Berkowitz RS (1995b) Polyadenylation polymorphism in the acetyltransferase I gene (NAT1) increases risk of colorectal cancer. Cancer Res 55: 3537-3542
6. Brockmoller J, Cascorbi I, Kerb R and Roots I (1996) Combined analysis of inherited polymorphisms in arylamine N-acetytransferase 2, glutathione S-transferases MJ and TL microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56: 3915-3925
7. Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R and Miller AB (1989) Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer 44: 626-628
8. p3 (p4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86: 7696-7700
9. Chiou HY, Hsuch YM, Liaw KF, Horng SF, Chiang MH, Pu YS, Lin JS, Huang CH and Chen CJ (1995) Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res 55: 1296-1300
10. Cluade J, Kunze E, Frentzel-Beyme R, Paczkowski K, Schneider J and Schubert H (1986) Life-style and occupational risk factors in cancer of the lower urinary tract. Am J Epidemiol 124: 578-589.
11. Fleming CM, Persad R, Kaisary A, Smith P, Adedoyin A, Porter J, Wilkinson GR and Branch RA (1994) Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer. Pharmacogenetics 4: 199-207
12. Frederickson SM, Messing EM, Resnikoff CA and Swaminathan S (1994) Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells. Cancer Epidemiol Biomark Prev 3: 25-32
13. Grant DM, Vohra P, Avis Y and Ima A (1992) Detection of a new polymorphism of human arylamine N-acetyltransferase (NAT1) using p-aminosalicylic acid as an in vivo probe. J Basic Clin Physiol Pharmacol 3: 244
14. Hein DW, Rustan TD, Doll MA, Bucher KD, Ferguson RJ, Feng Y, Furman EJ and Gray K (1992) Acetyltransferases and susceptibility to chemicals. Toxicol Lett 64/65: 123-130
15. Hickman D and Sim E (1991) N-acetyltransferase polymorphism comparison of phenotype and genotype in humans. Biochem Pharmacol 42: 1007-1014
16. International Agency for Research on Cancer (1986) Tobacco Smoking. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Vol. 38, pp. 35-394. International Agency for Research on Cancer: Lyon.
17. Jensen OM, Wahrendorf J, Blettner M, Knudsen JB and Sorensen BL (1987) The Copenhagen case-control study of bladder cancer: role of smoking in invasive and non-invasive bladder tumours. J Epidemiol Community Health 41: 30-36
18. Kadlubar FF and Badawi AF (1995) Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis. Toxicol Lett 82/83: 627-632
19. Kato R and Yamazoe Y (1994) Metabolic activation of N-hydroxylated metabolites of carcinogenic and mutagenic arylamines and arylamides by esterification. Drug Metabolism Rev 26: 413-430
20. Kirlin WG, Trinidad A, Yerokun T, Ogolla F, Ferguson RJ, Andrews AF, Brady PK and Hein DW (1989) Polymorphic expression of acetyl coenzyme A-dependent O-acetyltransferase-mediated activation of N-hydroxyarylamines by human bladder cytosols. Cancer Res 49: 2448-2454
21. Lin HJ, Han CY, Lin BK and Hardy S (1993) Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: application to metabolic epidemiology. Am J Hum Genet 52: 827-834
22. Lopez-Abente G, Gonzalez CA, Errezola M, Escolar A, Lzarzugaza I, Nebot M and Riboli E (1991) Tobacco smoke inhalation pattern, tobacco type, and bladder cancer in Spain. Am J Epidemiol 134: 830-839
23. Okkels H, Sigsgaard T, Wolf H and Autrup H (1997) Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomark Prev 6: 225-231
24. Risch A, Wallace DMA, Bathers S and Sim E (1995) Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Human Mol Genet 4: 231-236
25. Schairer C, Hartge P, Hoover RN and Silverman DT (1988) Racial differences in bladder cancer risk: a case-control study. Am J Epidemiol 128: 1027-1037
26. Skipper PL and Tannenbaum SR (1994) Molecular dosimetry of aromatic amines in human populations. Environ Health Perspect 102: 17-21
27. Smith BJ, Bebruin L, Josephy PD and Eling TE (1992) Mutagenic activation of benzidine requires prior bacterial acetylation and subsequent conversion by prostaglandin-H synthase to 4-nitro-4(acetylamino)biphenyl. Chem Res Toxicol 5: 431-439
28. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, Mohler JL and Bell DA (1998) The role of N-acetylation polymorphisms at NAT1 and NAT2 in smoking-associated bladder cancer: evidence of a gene gene-exposure three way interaction. Cancer Res 58: 3603-3610
29. Vatsis KP and Weber WW (1993) Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 locus. Arch Biochem Biophys 301: 71-76
30. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DAP, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T and Tamazoc Y (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics 5: 1-9
31. Vincis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G and Tannenbaum SR (1994) Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369: 154-156
32. Weber WW and Vatsis KP (1993) Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics 3: 209-212